Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.
Key findingSemaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, provid
What the researchers found
Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Measured cocaine self-administration, seeking behavior, and dopamine levels in nucleus accumbens. Semaglutide showed superiority over shorter-acting GLP-1 agonists.
How the study worked
In publication.
Who was studied
Rats in cocaine self-administration and seeking paradigms
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 98, 1-10
Citation
Aranäs, Cajsa; Caffrey, Antonia; Edvardsson, Christian E; Schmidt, Heath D; Jerlhag, Elisabet. (2025). Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 98, 1-10. https://doi.org/10.1016/j.euroneuro.2025.07.001